ALLARITY THERAPEUTICS INC (ALLR) Stock Price, Quote, News and Overview
NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD
ALLR Quote, Performance and Key Statistics
0.9909
-0.04 (-3.8%)
The current stock price of ALLR is 0.9909 USD. In the past month the price decreased by -0.91%. In the past year, price decreased by -97.74%.
ALLR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About ALLR
Company Profile
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2021-12-21. The firm is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. The company has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
Company Info
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 6
Company Website: https://allarity.com/
Investor Relations: https://allarity.com/investors/
Phone: 14014264664
ALLARITY THERAPEUTICS INC / ALLR FAQ
What is the stock price of ALLARITY THERAPEUTICS INC today?
The current stock price of ALLR is 0.9909 USD. The price decreased by -3.8% in the last trading session.
What is the ticker symbol for ALLARITY THERAPEUTICS INC stock?
The exchange symbol of ALLARITY THERAPEUTICS INC is ALLR and it is listed on the Nasdaq exchange.
On which exchange is ALLR stock listed?
ALLR stock is listed on the Nasdaq exchange.
What is ALLARITY THERAPEUTICS INC worth?
ALLARITY THERAPEUTICS INC (ALLR) has a market capitalization of 16.86M USD. This makes ALLR a Nano Cap stock.
How many employees does ALLARITY THERAPEUTICS INC have?
ALLARITY THERAPEUTICS INC (ALLR) currently has 6 employees.
What are the support and resistance levels for ALLARITY THERAPEUTICS INC (ALLR) stock?
ALLARITY THERAPEUTICS INC (ALLR) has a support level at 0.7 and a resistance level at 1.03. Check the full technical report for a detailed analysis of ALLR support and resistance levels.
Should I buy ALLARITY THERAPEUTICS INC (ALLR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALLR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALLR, evaluating the profitability, health, valuation and growth aspects
- ALLARITY THERAPEUTICS INC (ALLR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALLARITY THERAPEUTICS INC (ALLR) Sales and EPS estimates to see what analysts future expectations are.
- ALLARITY THERAPEUTICS INC (ALLR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALLARITY THERAPEUTICS INC (ALLR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALLARITY THERAPEUTICS INC (ALLR) Stock Chart to make your own analysis
- ALLARITY THERAPEUTICS INC (ALLR) Latest news and press-releases to stay up to date.
Does ALLARITY THERAPEUTICS INC (ALLR) stock pay dividends?
ALLR does not pay a dividend.
What is the Price/Earnings (PE) ratio of ALLARITY THERAPEUTICS INC (ALLR)?
ALLARITY THERAPEUTICS INC (ALLR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-933.21).
What is the Short Interest ratio of ALLARITY THERAPEUTICS INC (ALLR) stock?
The outstanding short interest for ALLARITY THERAPEUTICS INC (ALLR) is 17.79% of its float. Check the ownership tab for more information on the ALLR short interest.
ALLR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALLR. When comparing the yearly performance of all stocks, ALLR is a bad performer in the overall market: 96.04% of all stocks are doing better.
ALLR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLR. While ALLR seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALLR Financial Highlights
Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -933.21. The EPS increased by 99.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -95.31% | ||
| ROE | -149.82% | ||
| Debt/Equity | 0 |
ALLR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ALLR. The Buy consensus is the average rating of analysts ratings from 6 analysts.